On 15-17 May, the EPAD (European Prevention of Alzheimer’s Dementia) General Assembly meeting took place in Geneva, Switzerland. EPAD is a unique and ground-breaking European initiative to streamline the testing and development of preventative treatments for Alzheimer’s disease.
Several AMYPAD young researchers joined the educational workshops organised for the Early-Career Researchers. These events provided an opportunity to learn and share practices on how to translate the research to a large audience and how to provide a good peer-review of a scientific paper. Organisers highly appreciated the feedback provided by the young members attending the meeting.
On the final day, the EPAD consortium gathered for an EPAD Academy session, welcoming oral presentations from six early-career researchers. The session was a great opportunity for presenting AMYPAD. We are pleased that Lyduine Collij from VUmc presented her work within the AMYPAD project. In her talk titled “Staging cortical amyloid deposition using PET imaging”, Lyduine presented the construction of a generalisable model for staging cortical amyloid burden across multiple cohorts and radiotracers.
To keep up to date with EPAD’s progress, visit the website http://ep-ad.org/.
The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.